These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9816108

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
    Tortora G, Ciardiello F, Damiano V, Pepe S, Bianco C, di Isernia G, Davies SL, North P, Harris AL, Hickson ID.
    Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
    [Abstract] [Full Text] [Related]

  • 4. Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells.
    Martínez-Lacaci I, De Santis M, Kannan S, Bianco C, Kim N, Wallace-Jones B, Wechselberger C, Ebert AD, Salomon DS.
    J Cell Physiol; 2001 Feb; 186(2):233-42. PubMed ID: 11169460
    [Abstract] [Full Text] [Related]

  • 5. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 6. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
    Schendel DJ, Gansbacher B.
    Cancer Res; 1993 Sep 01; 53(17):4020-5. PubMed ID: 8358731
    [Abstract] [Full Text] [Related]

  • 9. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 10. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells.
    Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS.
    Mol Carcinog; 1992 Oct 15; 6(1):43-52. PubMed ID: 1354442
    [Abstract] [Full Text] [Related]

  • 11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 15; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 12. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT.
    Gene Ther; 1997 Apr 15; 4(4):317-22. PubMed ID: 9176517
    [Abstract] [Full Text] [Related]

  • 13. Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells.
    Pepe S, Ruggiero A, Tortora G, Ciardiello F, Garbi C, Yokozaki H, Cho-Chung YS, Clair T, Skalhegg BS, Bianco AR.
    Cytometry; 1994 Jan 01; 15(1):73-9. PubMed ID: 8162827
    [Abstract] [Full Text] [Related]

  • 14. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G.
    Int J Cancer; 2000 Mar 01; 85(5):710-5. PubMed ID: 10699953
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
    Cignetti A, Guarini A, Gillio Tos A, Reato G, Foa R.
    Cancer Gene Ther; 2000 Feb 01; 7(2):167-76. PubMed ID: 10770624
    [Abstract] [Full Text] [Related]

  • 16. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells.
    Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon A, Clair T, Cho-Chung YS, Bianco AR, Ciardiello F.
    Oncogene; 1994 Nov 01; 9(11):3233-40. PubMed ID: 7936647
    [Abstract] [Full Text] [Related]

  • 17. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
    Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G.
    Cancer Res; 1988 May 01; 48(9):2372-6. PubMed ID: 3258541
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 01; 5(3):153-8. PubMed ID: 10641573
    [Abstract] [Full Text] [Related]

  • 19. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
    Gwin JL, Gercel-Taylor C, Taylor DD, Eisenberg B.
    J Surg Res; 1996 Jan 01; 60(1):129-36. PubMed ID: 8592403
    [Abstract] [Full Text] [Related]

  • 20. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.